Xtant Medical Holdings (Xtant Medical Holdings) Cash, Cash Equivalents, Marketable Securities : $4.5 Mil (As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Xtant Medical Holdings Cash, Cash Equivalents, Marketable Securities?

Xtant Medical Holdings's quarterly cash, cash equivalents, marketable securities declined from Sep. 2023 ($8.66 Mil) to Dec. 2023 ($5.72 Mil) but then stayed the same from Dec. 2023 ($5.72 Mil) to Mar. 2024 ($4.55 Mil).

Xtant Medical Holdings's annual cash, cash equivalents, marketable securities increased from Dec. 2021 ($18.24 Mil) to Dec. 2022 ($20.30 Mil) but then declined from Dec. 2022 ($20.30 Mil) to Dec. 2023 ($5.72 Mil).

Xtant Medical Holdings Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Xtant Medical Holdings's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xtant Medical Holdings Cash, Cash Equivalents, Marketable Securities Chart

Xtant Medical Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash, Cash Equivalents, Marketable Securities

Get a 7-Day Free Trial

5.24

2.34

18.24

20.30

5.72

Xtant Medical Holdings Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial															5.18	4.14	8.66	5.72	4.55

Xtant Medical Holdings Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Xtant Medical Holdings (AMEX:XTNT) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Xtant Medical Holdings Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Xtant Medical Holdings's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Xtant Medical Holdings (Xtant Medical Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xtant Medical Holdings Inc (AMEX:XTNT) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

XMS:Germany

Address

664 Cruiser Lane, Belgrade, MT, USA, 59714

Website

http://www.xtantmedical.com

Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the US.

Executives

Kevin D Brandt	officer: VP & Chief Commercial Officer	11621 RESEARCH CIRCLE, ALACHUA FL 32615
Lori D Mitchell-keller	director	664 CRUISER LANE, BELGRADE MT 59714
Jonn R. Beeson	director	664 CRUISER LANE, BELGRADE MT 59714
Scott C Neils	officer: Interim CFO	664 CRUISER LANE, BELGRADE MT 59714
Mark A. Schallenberger	officer: Chief Operations Officer	664 CRUISER LANE, BELGRADE MT 59714
Sean E Browne	officer: President and CEO	664 CRUISER LANE, BELGRADE MT 59714
Stavros G. Vizirgianakis	director	1/16-18 TENNYSON ST., WILLIAMSTOWN NORTH, VICTORIA CA 3016
Orbimed Rof Ii Llc	director, 10 percent owner	601 LEXINGTON AVE., 54TH FLOOR, NEW YORK NY 10022
Greg Jensen	officer: VP, Finance and Interim CFO	664 CRUISER LANE, BELGRADE MT 59714
Ronald G. Berlin	officer: VP & Chief Operations Officer	664 CRUISER LANE, BELGRADE MT 59714
Kathie J. Lenzen	officer: SVP Fiance & Admin. & CFO	664 CRUISER LANE, BELGRADE MT 59714
Orbimed Advisors Llc	10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Matthew Rizzo	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Michael Eggenberg	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Robert Mcnamara	director	C/O LDR HOLDING CORPORATION, 13785 RESEARCH BOULEVARD, SUITE 200, AUSTIN TX 78750